Clifford Capital Partners LLC Sells 26,149 Shares of Kenvue Inc. (NYSE:KVUE)

Clifford Capital Partners LLC cut its stake in Kenvue Inc. (NYSE:KVUE) by 3.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 762,302 shares of the company’s stock after selling 26,149 shares during the quarter. Kenvue comprises about 3.5% of Clifford Capital Partners LLC’s investment portfolio, making the stock its 10th biggest position. Clifford Capital Partners LLC’s holdings in Kenvue were worth $17,632,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. RBO & Co. LLC grew its holdings in Kenvue by 40.7% during the 3rd quarter. RBO & Co. LLC now owns 991,419 shares of the company’s stock valued at $22,932,000 after purchasing an additional 286,929 shares in the last quarter. Townsquare Capital LLC grew its stake in shares of Kenvue by 25.3% during the third quarter. Townsquare Capital LLC now owns 52,713 shares of the company’s stock valued at $1,219,000 after acquiring an additional 10,629 shares in the last quarter. Brooklyn Investment Group purchased a new stake in shares of Kenvue during the third quarter worth about $71,000. FMR LLC lifted its stake in shares of Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after acquiring an additional 3,075,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Kenvue by 5.5% in the third quarter. The Manufacturers Life Insurance Company now owns 2,138,576 shares of the company’s stock valued at $49,465,000 after purchasing an additional 110,849 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $24.12 on Wednesday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average of $22.87 and a two-hundred day moving average of $20.92. The company has a market cap of $46.24 billion, a P/E ratio of 43.85, a PEG ratio of 2.20 and a beta of 1.36. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the previous year, the firm posted $0.31 EPS. The business’s revenue for the quarter was down .4% compared to the same quarter last year. As a group, analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.40%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday, September 23rd. UBS Group raised their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.